You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海醫藥(601607.SH):I037完成中國II期臨牀試驗結果分析
格隆匯 11-29 15:38

格隆匯11月29日丨上海醫藥(601607.SH)公佈,公司與順天醫藥生技股份有限公司簽訂《合作協議》,取得I037(以下稱“LT3001”或“該項目”)在中國大陸地區開發、生產和銷售等的獨佔權益(詳見公司公吿臨2019-085號)。2020年9月,該項目獲國家藥品監督管理局批准開展臨牀試驗(詳見公司公吿臨2020-052號)。近日,公司完成LT3001中國II期臨牀試驗結果分析。

注射用LT3001屬於全球首創結合靶向溶栓和腦神經保護功能的急性腦卒中治療創新藥項目,擬用於急性缺血性腦卒中的治療。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account